Most Viewed Articles of 2023

2023, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year. Top 20 Radiopharma Companies Based on Market Cap Shots: Integrating scintigraphy with…

BySaurabh ChaubeyJanuary 2, 2024

INSIGHTS+

Top Performing Drug – Trikafta/Kaftrio (May Edition)

Shots:In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Trikafta/Kaftrio as the top-performing drug of the monthTrikafta is a combination of ivacaftor, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis in pediatric patients who have at least one…

BySenior EditorMay 24, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in April 2023

Shots:The US FDA approved 6 NDAs and 4 BLA in April 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 36 novel products in 2023In April 2023, the major highlights drugs were, Trikafta approval for children with cystic fibrosis, Qalsody for the treatment of amyotrophic…

BySenior EditorMay 17, 2023

THOUGHTSPOT

Getting on with Rare Disease Therapeutic Options (Orphan Disease Therapies)

Shots:With the healthcare sector moving ahead with its technological advances, there is still an unexplored section in therapeutics that requires much more attention. Through innovations, life science companies have evolved to make breakthrough discoveries in many focus areas, but when it comes to the rare disease segment, all our endeavors seem to be bleak…

BySaurabh ChaubeyMarch 14, 2023

Most Viewed Articles of 2023

Top Performing Drug – Trikafta/Kaftrio (May Edition)

Insights+: The US FDA New Drug Approvals in April 2023

Getting on with Rare Disease Therapeutic Options (Orphan Disease Therapies)

Contact US

OUR INFORMATION

FOLLOW US